Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin?

In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment.

Secondary analysis of a randomised trial · Diabetes Care 2025

Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk?

In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial.

Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients?

In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo.

Randomized trial · NEJM 2025

Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642.

Chapters

0:00 Intro

0:38 The trial

3:07 My take

3:49 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en